Oligodendroglial ganglioglioma

Kalyan R, Olivero WC (1987) Ganglioglioma: a correlative clinicopathological and radiological study of ten surgically treated cases with follow-up. Neurosurgery 20:428–433

Luyken C, Blumcke I, Fimmers R et al (2004) Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer (Phila) 101:146–155

Miller DC, Frederick F et al (1993) Central nervous system gangliogliomas. Part 1: Pathology. J Neurosurg 79:859–866

Prayson RA, Khajavi K, Comair YG (1995) Cortical architectural abnormalities and MIB1 immunoreactivity in gangliogliomas: a study of 60 patients with intracranial tumors. J Neuropathol Exp Neurol 54:513–520

Nair V, suri VS, Tatke M et al (2004) Gangliogliomas: a report of five cases. Indian J Cancer 41:41–46

Rousseau A, Nutt CL, Betensky RA et al (2006) Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol 65:1149–1156

Ligon KL, Alberta JA, Kho AT et al (2004) The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol 63:499–509

Zhou Q, Choi G, Anderson DJ (2001) The bHLH transcription factor Olig2 promotes oligodendrocyte differentiation in collaboration with NKX2.2. Neuron 31:791–807

Qi Y, Cai J, Wu Y et al (2001) Control of oligodendrocyte differentiation by the NKX2.2 homeodomain transcription factor. Development (Camb) 128:2723–2733

Sun T, Dong H, Wu L et al (2003) Cross-repressive interaction of the Olig2 and NKX2.2 transcription factors in developing neural tube associated with formation of a specific physical complex. J Neurosci 23:9547–9556

Jeuken JW, von Deimling A, Wesseling P (2004) Molecular pathogenesis of oligodendroglial tumors. J Neuro-oncol 70:161–181

Okamoto Y, Di Patre PL, Burkhard C et al (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49–56

Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126

Perry A, Burton SS, Fuller GN et al (2010) Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall. Acta Neuropathol 120:237–252

Blumcke I, Giencke K, Wardelmann E et al (1999) The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsia. Acta Neuropathol 97:481–490

Nagaishi M, Arai M, Osawa T et al. (2011) An immunohistochemical finding in glioneuronal lesions associated with epilepsy: the appearance of nestin-positive, CD34-positive and tau-accumulating cells. Neuropathology 31: doi: 10.111/j.1440-1789.2010.01188.x

Im SH, Chung CK, Cho BK et al. (2002) Intracranial ganglioglioma: preoperative characteristics and oncologic outcome after surgery. J Neuro-oncol 59:173–183

Rumana CS, Valadka AB, Contant CF (1999) Prognostic factors in supratentorial ganglioglioma. Acta Neurochir 141:63–69

Allegranza A, Pileri S, Frank G et al (1990) Cerebral ganglioglioma with anaplastic oligodendroglial component. Histopathology (Oxf) 17:439–441

Johnson MD, Mark T et al (2001) Oligodendroglial ganglioglioma with anaplastic features arising from the thalamus. Pediatr Neurosurg 34:301–305